Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Validation of respiratory epithelial functional assessment in cystic fibrosis patients treated with Orkambi
2018-002624-16Phase 4
- Sponsor
- Assistance publique - Hôpitaux de Paris
- Start
- Nov 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of lumacaftor + ivacaftor in cystic fibrosis (CF), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Change in percent predicted FEV1 at 24 weeks.
02
Drugs
lumacaftor + ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2018-002624-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-002624-16.